Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evolutionary implications of <i>NOTCH2NLC</i> mutations: brain structural changes in neuronal intranuclear inclusion disease revealed by comprehensive morphometry.

Brain communications·2026

Same author

An updated catalog of earthquakes with M ≥ 4.7 from 2300 BC to 2024 AD for the China's new seismic zonation map.

Scientific data·2026

Same author

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

Journal of bone oncology·2026

Same author

Retinal thinning and dorsal visual stream degeneration in neuronal intranuclear inclusion disease: Multimodal MRI/OCT evidence with network and mediation analyses.

Neurobiology of disease·2026

Same author

Single-atom Cu<sub>1</sub>/ZrO<sub>2</sub> coupled with SAPO-34 enhances CO<sub>2</sub> hydrogenation to light olefins.

Nanoscale·2026

Same author

Realization of Low Interfacial Tension and High Stability in Polybutadiene Emulsions via Branched-Zwitterionic Surfactant Mixtures: A Molecular Dynamics Study.

ACS applied materials & interfaces·2026

Search research articles

Related Experiment Video

Updated: May 23, 2026

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

Postformulation peptide drug loading of nanostructures.

Hua Pan¹, Jon N Marsh, Eric T Christenson

¹Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.

Methods in Enzymology

|March 28, 2012

Summary

Anticancer peptides show promise but face delivery challenges. This study explores incorporating therapeutic peptides into lipid nanostructures for improved anticancer drug delivery and efficacy.

More Related Videos

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Related Experiment Videos

Last Updated: May 23, 2026

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Area of Science:

Biomedical Engineering
Nanotechnology
Drug Delivery

Background:

Cytolytic peptides offer anticancer potential due to their membrane-disrupting properties, which are less prone to resistance.
Peptides are attractive therapeutics due to specificity, affinity, and reduced toxicity, but face challenges in delivery, in vivo stability, and bioavailability.
Effective clinical application of peptide drugs necessitates combining potent peptides with advanced delivery systems.

Purpose of the Study:

To present methods for integrating peptide drugs into lipidic nanostructures postformulation.
To detail the physical characterization of these peptide-nanostructure complexes.
To evaluate the therapeutic efficacy of these nanostructured peptide drugs in vitro and in vivo.

Main Methods:

Postformulation insertion of peptide drugs into lipidic nanostructures.
Physical characterization techniques for peptide-nanostructure complexes.
In vitro and in vivo evaluation of therapeutic effectiveness.

Main Results:

Demonstrated successful incorporation of peptide drugs into lipidic nanostructures.
Characterized the physical properties of the resulting peptide-nanostructure complexes.
Evaluated and confirmed the therapeutic effectiveness of the nanocarried peptides.

Conclusions:

Developing robust delivery methodologies is crucial for the clinical translation of peptide therapeutics.
Postformulation insertion into lipidic nanostructures is a viable strategy for enhancing peptide drug delivery.
This approach holds promise for improving the in vitro and in vivo efficacy of anticancer peptides.